Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. Its lead development candidate, ivonescimab, is a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and is also in Phase III clinical trials for the treatment of non-small lung cancer. The company has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. Summit Therapeutics Inc. was founded in 2003 and is headquartered in Miami, Florida.

Summit Therapeutics Inc.

Citi analyst Yigal Nochomovitz maintained a Buy rating on Summit Therapeutics on December 2 and set a price target of $131.90. The company’s shares...

Current Quarter	$-0.22	Next Quarter	$-0.25
Current Year	$-1.21	Next Year	$-0.82
QoQ Growth	-13.6%	YoY Growth	+32.2%
3Y EPS CAGR	+31.4%	Target Price	$32.31
Consensus	Buy	Upside	+83.9%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SMMT	$17.57	-2.33%	1.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SMMT	$17.57	-2.3%	1.59M
3
4
5
6

SMMT

SMMT

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Summit Therapeutics Inc. Data in Excel

Get Summit Therapeutics Inc. Data in Excel